Neffy gained traction: ARS reported $26.2 million in second-quarter U.S. net product revenue, while total revenue reached $33.7 million. U.S. market share increased to 5% from 2.5% a year earlier, with more than 16,000 unique prescribers. Commercial and financial strategy reset: The company is shifting away from broad consumer advertising toward targeted healthcare-provider promotion and plans to cut second-half 2026 cash-based SG&A and R&D expenses by more than 40%.
ARS expects to reach cash-flow breakeven by the end of 2027. CSU program timeline moved: The interim readout from neffy's Phase IIb chronic spontaneous urticaria trial is now expected in the first quarter of 2027, later than previously anticipated, as patients complete the required flare episodes. ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected path to cash-flow breakeven by the end of 2027.
Casale, hosting his first earnings call as CEO, said the company has established three priorities: targeted healthcare-provider commercial execution, financial discipline and pipeline expansion beginning with chronic spontaneous urticaria, or CSU. → Lumentum Just Delivered the AI Growth Investors Wanted ARS reported second-quarter U.S. net product revenue of $26.2 million. Total revenue, including net product, collaboration and supply revenue, was $33.7 million. Neffy's total U.S. market share reached 5% during the quarter, compared with 2.5% a year earlier, according to Casale.
In the company's field-sales targeted universe, market share rose to 8% from 4% in the prior-year period. ARS also reported more than 16,000 unique neffy prescribers during the quarter, more than triple the prior-year level. → Joby's Defense Pivot Accelerates With $500M Resonant Sciences Deal Casale said neffy is sold into what he described as a prevention-based market, because patients are prescribed the rescue therapy and carry it before an allergic event occurs. As a result, he said provider behavior is particularly important to adoption.
"Closing the gap relies less on broad consumer awareness and far more on changing long-established provider prescribing habits," Casale said. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be The company has completed an expansion of its field sales organization and intends to focus the team on high-value prescribers representing 44% of the total market opportunity. Casale said neffy holds approximately 8% market share in the field-targeted universe, compared with about 1% in the non-targeted universe. ARS plans to begin reporting both total market share and share within its field-targeted call universe each quarter.
Casale said the company expects steady share gains over successive quarters rather than an immediate increase. Casale said ARS invested heavily at launch in broad direct-to-consumer advertising, including linear and closed-circuit television. While those efforts built awareness, he said such advertising can be expensive and may not consistently convert into utilization in a prevention-oriented market.
Extract — continue reading at the source.
